- Home
- TVRD vs DRK Comparison
TVRD vs DRK Comparison
Compare TVRD & DRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVRD | DRK |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 26.9M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TVRD | DRK |
|---|---|---|
| Price | $1.29 | $2.94 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $29.50 | N/A |
| AVG Volume (30 Days) | 189.8K | ★ 219.3K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.01 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $911,000.00 | ★ $11,181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 959.30 | N/A |
| 52 Week Low | $0.93 | $2.70 |
| 52 Week High | $43.65 | $3.19 |
Technical Indicators
Market Signals| Indicator | TVRD | DRK |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 41.82 |
| Support Level | N/A | $2.70 |
| Resistance Level | $2.02 | N/A |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 35.51 | 38.78 |
Price Performance
Historical ComparisonAbout TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.